Skip to content
St. Josephs Hospital – Parkersburg, West Virginia
  • Home
  • Mycoplasma Detection Kits – Conventional PCR
  • potent necroptosis inhibitor biovision nec 1s
  • SPHERO Ultra Rainbow Fluorescent Particles
  • Cell Counting Package deal-8
  • Assay Kits
  • Antibodies
  • Panel
  • Reagents
  • Biology Cells
  • Reagents
  • Exosomes
  • Particles
  • Gels
  • cDNA
  • Enzymes
  • Culture Cells
  • Nki C3
  • Anti C Myc
  • RNA
  • Protein Carbonyls
  • Human Bnp
  • Western Blotting Blocking
  • Sample Buffer Sds Page
  • Services Listing
  • Specialty Services
  • Volunteer Opportunities
  • Bill Payment
  • Advanced Medical Technologies
  • Contact Us
Close Button

The development and controversy of competitive endogenous RNA hypothesis in non-coding genes

| Steven WashingtonSteven Washington | 0 Comment
stjosephs-hospital

As a momentous post-transcriptional regulator, microRNAs (miRNAs) are attracting more and more attention. The classical miRNAs regulated mechanism shows it binds to the targets’ 3’UTR thus play the role in post-transcription.

Meanwhile, single miRNA can target multiple genes, so those should compete to bind that miRNA. Vice versa, single gene can sponge mass of miRNAs as well. Thus the competitive endogenous RNAs (ceRNAs) hypothesis was put forward in 2011.

The ceRNA hypothesis has made huge achievements, in particular in non-coding genes, which including long non-coding RNAs (lncRNAs), circle RNAs (circRNAs) and pseudogenes, even viral transcripts. It also contributed greatly to epigenetics development.

However, an increasing number of controversies have occurred with applause. Based on this situation, this review introduces something in detail about the ceRNAs hypothesis achieved in lncRNAs,circRNAs, pseudogenes and viral transcripts, respectively. Meanwhile, it also covers controversy of the ceRNAs hypothesis

RNA silencing of hormonal biosynthetic genes impairs larval growth and development in cotton bollworm, Helicoverpa armigera

The cotton bollworm, Helicoverpa armigera, is a highly polyphagous pest, causing enormous losses to various economically important crops. The identification and in vitro functional validation of target genes of a pest is a prerequisite to combat pest via host-mediated RNA interference (RNAi).

In the present study, six hormonal biosynthesis genes of H. armigera were chosen and evaluated by feeding insect larvae with dsRNAs corresponding to each target gene, viz., juvenile hormone acid methyltransferase (HaJHAMT), prothoracicotropic hormone (HaPTTH), pheromone biosynthesis-activating peptide (HaPBAP), molt regulating transcription factor (HaHR3), activated protein 4 (HaAP-4) and eclosion hormone precursor (HaEHP).

The loss of function phenotypes for these hormonal genes were observed by releasing second instar larvae on to artificial diet containing target gene-specific dsRNAs. Ingestion of dsRNAs resulted in mortality ranging from 60% to 90%, reduced larval weight, phenotypic deformities and delayed pupation. The quantitative real-time PCR (qRT-PCR) analysis showed that the target gene transcript levels were decreased drastically (31% to 77%) as compared to control or unrelated control (GFP-dsRNA), and correlated well with the mortality and developmental defects of larvae.

Also, a comparison of the silencing efficacy of un-diced long HaPTTH -dsRNAwith RNase III diced HaPTTH-dsRNA (siRNAs) revealed that long dsRNAs were more efficient in silencing the target gene. These results indicated that the hormonal biosynthesis genes have varied sensitivity towards RNAi and could be the vital targets for insect resistance in crop plants like cotton which are infested by H. armigera.

 

Conserved Patterns in Developmental Processes and Phases, Rather than Genes, Unite the Highly Divergent Bilateria

Bilateria are the predominant clade of animals on Earth. Despite having evolved a wide variety of body plans and developmental modes, they are characterized by common morphological traits. By default, researchers have tried to link clade-specific genes to these traits, thus distinguishing bilaterians from non-bilaterians, by their gene content.

Here we argue that it is rather biological processes that unite Bilateria and set them apart from their non-bilaterian sisters, with a less complex body morphology. To test this hypothesis, we compared proteomes of bilaterian and non-bilaterian species in an elaborate computational pipeline, aiming to search for a set of bilaterian-specific genes.

Despite the limited confidence in their bilaterian specificity, we nevertheless detected Bilateria-specific functional and developmental patterns in the sub-set of genes conserved in distantly related Bilateria. Using a novel multi-species GO-enrichment method, we determined the functional repertoire of genes that are widely conserved among Bilateria. Analyzing expression profiles in three very distantly related model species-D. melanogaster, D. rerio and C. elegans-we find characteristic peaks at comparable stages of development and a delayed onset of expression in embryos. In particular, the expression of the conserved genes appears to peak at the phylotypic stage of different bilaterian phyla.

In summary, our study illustrate how development connects distantly related Bilateria after millions of years of divergence, pointing to processes potentially separating them from non-bilaterians. We argue that evolutionary biologists should return from a purely gene-centric view of evolution and place more focus on analyzing and defining conserved developmental processes and periods.

stjosephs-hospital

stjosephs-hospital

The impact of cross-kingdom molecular forensics on Genetic privacy

Recent advances in metagenomic technology and computational prediction may inadvertently weaken an individual’s reasonable expectation of privacy. Through cross-kingdom genetic and metagenomic forensics, we can already predict at least a dozen human phenotypes with varying degrees of accuracy.

There is also growing potential to detect a “molecular echo” of an individual’s microbiome from cells deposited on public surfaces. At present, host genetic data from somatic or germ cells provide more reliable information than microbiome samples.

However, the emerging ability to infer personal details from different microscopic biological materials left behind on surfaces requires in-depth ethical and legal scrutiny. There is potential to identify and track individuals, along with new, surreptitious means of genetic discrimination.

This commentary underscores the need to update legal and policy frameworks for genetic privacy with additional considerations for the information that could be acquired from microbiome-derived data. The article also aims to stimulate ubiquitous discourse to ensure the protection of genetic rights and liberties in the post-genomic era. Video abstract.

MiR-340 promotes the proliferation of vascular smooth muscle cells by targeting von Hippel-Lindau tumor suppressor (VHL) Gene

MiRNAs play key roles in the proliferation of vascular smooth muscle cells (VSMCs). However, the roles and underlying mechanism of miRNAs in VSMCs are not fully understood. The aim of this study was to evaluate the role of miR-340 in the proliferation of VSMCs.

 

The expression levels of miR-340 and von Hippel-Lindau tumor-suppressor (VHL) in VSMCs induced by platelet-derived growth factor (PDGF) -BB or fetal bovine serum (FBS) were measured by q-PCR. The effects of miR-340 and VHL on cell proliferation and invasion were evaluated by CCK-8 assay.

Target gene prediction and screening as well as luciferase reporter assay were performed to verify the downstream target genes of miR-340. Western blotting was used to detect the protein expression levels of vascular endothelial growth factor (VEGF) and VHL.

Our results showed that the miR-340 was up-regulated in PDGF-BB_ENREF_1or FBS induced VSMCs. In addition, overexpression of miR-340 promoted VSMCs proliferation and invasion. Moreover, VHL was found to be a potential target for miR-340, and up-regulation of VHL inhibited VSMCs proliferation.

MiR-340 plays a critical role in VSMC proliferation and neointimal hyperplasia in rats carotid balloon injury model. Reduced expression levels of miR-340 promoted VHL-inhibited VSMCs proliferation. In conclusion, miR-340 may play a role in the regulation of proliferation of VSMCs by inhibition of VHL.

 

c-Myc(MYC699) Antibody

BNC470699-500 Biotium 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC699), CF647 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC400699-100 Biotium 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC699), CF640R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC400699-500 Biotium 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC699), CF640R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC400909-100 Biotium 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC909), CF640R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC400909-500 Biotium 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC909), CF640R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC550275-100 Biotium 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC275), CF555 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC550275-500 Biotium 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC275), CF555 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC550699-100 Biotium 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC699), CF555 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC550699-500 Biotium 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC699), CF555 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC550909-100 Biotium 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC909), CF555 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC550909-500 Biotium 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC909), CF555 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC400275-100 Biotium 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC275), CF640R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC400275-500 Biotium 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC275), CF640R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC430275-100 Biotium 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC275), CF543 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC430275-500 Biotium 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC275), CF543 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC430699-100 Biotium 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC699), CF543 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC430699-500 Biotium 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC699), CF543 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC430909-100 Biotium 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC909), CF543 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC430909-500 Biotium 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC909), CF543 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC470909-100 Biotium 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC909), CF647 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC470909-500 Biotium 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC909), CF647 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC800699-100 Biotium 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC699), CF680 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC800699-500 Biotium 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC699), CF680 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC800909-100 Biotium 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC909), CF680 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC800909-500 Biotium 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC909), CF680 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC810275-100 Biotium 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC275), CF680R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC810275-500 Biotium 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC275), CF680R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC810699-100 Biotium 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC699), CF680R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC810699-500 Biotium 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC699), CF680R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC810909-100 Biotium 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC909), CF680R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC810909-500 Biotium 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC909), CF680R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC610909-100 Biotium 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC909), CF660R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC610909-500 Biotium 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC909), CF660R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC610275-100 Biotium 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC275), CF660R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC610275-500 Biotium 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC275), CF660R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC610699-100 Biotium 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC699), CF660R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC610699-500 Biotium 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC699), CF660R conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNUM0275-50 Biotium 50uL
EUR 474
Description: Primary antibody against c-Myc(MYC275), 1mg/mL

c-Myc(MYC699) Antibody

BNUM0699-50 Biotium 50uL
EUR 474
Description: Primary antibody against c-Myc(MYC699), 1mg/mL

c-Myc(MYC909) Antibody

BNUM0909-50 Biotium 50uL
EUR 474
Description: Primary antibody against c-Myc(MYC909), 1mg/mL

c-Myc(MYC275) Antibody

BNCB0275-100 Biotium 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC275), Biotin conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNCB0275-500 Biotium 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC275), Biotin conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNCB0699-100 Biotium 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC699), Biotin conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNCB0699-500 Biotium 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC699), Biotin conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNCB0909-100 Biotium 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC909), Biotin conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNCB0909-500 Biotium 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC909), Biotin conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNCP0275-250 Biotium 250uL
EUR 459.6
Description: Primary antibody against c-Myc(MYC275), PerCP conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNCP0699-250 Biotium 250uL
EUR 459.6
Description: Primary antibody against c-Myc(MYC699), PerCP conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNCP0909-250 Biotium 250uL
EUR 459.6
Description: Primary antibody against c-Myc(MYC909), PerCP conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNCA0275-250 Biotium 250uL
EUR 459.6
Description: Primary antibody against c-Myc(MYC275), APC conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNCA0699-250 Biotium 250uL
EUR 459.6
Description: Primary antibody against c-Myc(MYC699), APC conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNCAP0909-100 Biotium 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC909), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNCAP0909-500 Biotium 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC909), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNCA0909-250 Biotium 250uL
EUR 459.6
Description: Primary antibody against c-Myc(MYC909), APC conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNCAP0275-100 Biotium 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC275), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNCAP0275-500 Biotium 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC275), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNCAP0699-100 Biotium 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC699), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNCAP0699-500 Biotium 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC699), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC940275-100 Biotium 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC275), CF594 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC940275-500 Biotium 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC275), CF594 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC940699-100 Biotium 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC699), CF594 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC940699-500 Biotium 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC699), CF594 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC940909-100 Biotium 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC909), CF594 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC940909-500 Biotium 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC909), CF594 conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNCH0275-100 Biotium 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC275), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNCH0275-500 Biotium 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC275), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNCH0699-100 Biotium 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC699), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNCH0699-500 Biotium 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC699), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNCH0909-100 Biotium 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC909), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNCH0909-500 Biotium 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC909), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNUB0909-100 Biotium 100uL
EUR 250.8
Description: Primary antibody against c-Myc(MYC909), Concentration: 0.2mg/mL

c-Myc(MYC909) Antibody

BNUB0909-500 Biotium 500uL
EUR 549.6
Description: Primary antibody against c-Myc(MYC909), Concentration: 0.2mg/mL

c-Myc(MYC275) Antibody

BNUB0275-100 Biotium 100uL
EUR 250.8
Description: Primary antibody against c-Myc(MYC275), Concentration: 0.2mg/mL

c-Myc(MYC275) Antibody

BNUB0275-500 Biotium 500uL
EUR 549.6
Description: Primary antibody against c-Myc(MYC275), Concentration: 0.2mg/mL

c-Myc(MYC699) Antibody

BNUB0699-100 Biotium 100uL
EUR 250.8
Description: Primary antibody against c-Myc(MYC699), Concentration: 0.2mg/mL

c-Myc(MYC699) Antibody

BNUB0699-500 Biotium 500uL
EUR 549.6
Description: Primary antibody against c-Myc(MYC699), Concentration: 0.2mg/mL

c-Myc(MYC275) Antibody

BNC040275-100 Biotium 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC275), CF405S conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC040275-500 Biotium 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC275), CF405S conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC040699-100 Biotium 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC699), CF405S conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC040699-500 Biotium 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC699), CF405S conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC040909-100 Biotium 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC909), CF405S conjugate, Concentration: 0.1mg/mL

c-Myc(MYC909) Antibody

BNC040909-500 Biotium 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC909), CF405S conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC050275-100 Biotium 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC275), CF405M conjugate, Concentration: 0.1mg/mL

c-Myc(MYC275) Antibody

BNC050275-500 Biotium 500uL
EUR 652.8
Description: Primary antibody against c-Myc(MYC275), CF405M conjugate, Concentration: 0.1mg/mL

c-Myc(MYC699) Antibody

BNC050699-100 Biotium 100uL
EUR 238.8
Description: Primary antibody against c-Myc(MYC699), CF405M conjugate, Concentration: 0.1mg/mL
Tags: dna ancestry, dna center of america, dna definition, dna function, dna hr block, dna hrblock login, dna ligase, dna meaning, dna molecule, dna painter, dna polymerase, dna project, dna questions answers, dna replication, dna research, dna sentinel login, dna stands for, dna strand, dna synthesis, dna testing, dna tests, dna vs rna, dnahrblock.com login, dnase, gelsas, gelsb, gelsd, gelsel, gelsemia, gelsemiums, gelsenkirchen, gelsenkirchen germany, gelsey, gelsey kirkland, gelseyn, gelsight, gelsomina, gelsomino, gelson's encino, gelson's market corporate office, gelson’s instacart, gelson’s market, gelsons logo, gelsonse, gelsosomo's, gelsosomo's crown point menu, gelsosomo's menu, gelsyn-3, pcdna3.1 - dyk, pcdna3.1 + /cat, pcdna3.1 cas9, pcdna3.1 egfp, pcdna3.1 flag, pcdna3.1 g418, pcdna3.1 gfp, pcdna3.1 ha, pcdna3.1 hygro, pcdna3.1 kozak, pcdna3.1 map, pcdna3.1 myc, pcdna3.1 neo, pcdna3.1 puro, pcdna3.1 t7, pcdna3.1 tag, pcdna3.1 v5, pcdna3.1 zeo

Post navigation

PREVIOUS Previous post: ePath: an online database towards comprehensive essential gene annotation for prokaryotes.
NEXT Next post: Genetic variations in autoimmune genes and VKH disease

Related Post

chromogen solution b

chromogen solution bchromogen solution b

QuickDetect  Hydroxylysine (Human) ELISA Package deal ( Catalog # E4714-100 ; 96 assays ; Storage at 4ºC ) 05/19 I. Introduction: Hydroxylysine (Hyl) is an amino acid which arises from

READ MOREREAD MORE
stjosephs-hospital

Utilizing genome-scale fashions to optimize nutrient present for sustained algal progress and lipid productivenessUtilizing genome-scale fashions to optimize nutrient present for sustained algal progress and lipid productiveness

Nutrient availability is essential for progress of algae and completely totally different microbes used for producing worthwhile biochemical merchandise. Figuring out the optimum ranges of nutrient provides to cultures can

READ MOREREAD MORE
stjosephs-hospital

Melting dsDNA Donor Molecules Vastly Improves Precision Genome Enhancing in CaenorhabditiselegansMelting dsDNA Donor Molecules Vastly Improves Precision Genome Enhancing in Caenorhabditiselegans

CRISPR genome modifying has revolutionized genetics in quite a few organisms. Contained in the nematode Caenorhabditiselegans one injection into every of the 2 gonad arms of an grownup hermaphrodite exposes

READ MOREREAD MORE
Easy-to-search healthcare libraries and quick gene reference directories
Easy-to-search healthcare libraries and quick gene reference directories

Recent Posts

  • Serum HER-2 assurance utilizing a centauer HER-2/neu unit (CLIA technique) in metastatic bosom disease
  • Innovative Bioprocess Strategies Combining Physiological Control and Strain Engineering of Pichia pastoris to Improve Recombinant Protein Production
  • fd speedy golgi stain equipment
  • Western Blot Stripping Buffer
  • Protein A, HRP conjugate

Gen Store Inc.

Categories

  • 100 Bp Plus Dna Ladder
  • Anti Bovine Serum Albumin Antibody
  • Anti Bsa Antibody
  • Anti C Myc
  • Antibodies
  • Assay Kits
  • Atp Bioluminescence Assay
  • Biology Cells
  • Bsa Biotin
  • cDNA
  • Cell Biolabs Inc
  • Cibacron Blue
  • Clia Kits
  • Culture Cells
  • Devices
  • DNA
  • DNA Testing
  • Elisa Kits
  • Enzymes
  • Equipments
  • Exosomes
  • Gels
  • Human Bnp
  • Isotypes
  • Medium & Serums
  • NATtrol
  • Nki C3
  • Panel
  • Particles
  • Pcr Kits
  • Peptides
  • Protein Carbonyl Assay
  • Protein Carbonyls
  • Ray Biotech Cytokine Array
  • Reagents
  • Recombinant Proteins
  • Ria Kits
  • RNA
  • Sample Buffer Sds Page
  • Test Kits
  • Vector & Virus
  • Western Blotting Blocking

Tags

dna ancestry dna definition dna hr block dna hrblock login dna painter dna replication dna testing dna tests gelson’s instacart gelson’s market gelsyn-3 isotopes definition isotopes half-life isotopes meaning isotypes antibody isotypes of antibodies and their function isotypes of ig isotypes of igg isotypes of immunoglobulin panel de control paneling paneling for walls panelist panel van particles in urine particles png particles synonym peptides 2 peptides ad peptides and ra peptides and retinol peptides and retinol usage peptides collagen peptides for bodybuilding peptides for eyes peptides for muscle peptides gw peptidesim peptides t3 peptides t4 peptides tadalafil rna-seq rna definition rna polymerase rna vs dna

Axis Shield

Categories

  • 100 Bp Plus Dna Ladder
  • Anti Bovine Serum Albumin Antibody
  • Anti Bsa Antibody
  • Anti C Myc
  • Antibodies
  • Assay Kits
  • Atp Bioluminescence Assay
  • Biology Cells
  • Bsa Biotin
  • cDNA
  • Cell Biolabs Inc
  • Cibacron Blue
  • Clia Kits
  • Culture Cells
  • Devices
  • DNA
  • DNA Testing
  • Elisa Kits
  • Enzymes
  • Equipments
  • Exosomes
  • Gels
  • Human Bnp
  • Isotypes
  • Medium & Serums
  • NATtrol
  • Nki C3
  • Panel
  • Particles
  • Pcr Kits
  • Peptides
  • Protein Carbonyl Assay
  • Protein Carbonyls
  • Ray Biotech Cytokine Array
  • Reagents
  • Recombinant Proteins
  • Ria Kits
  • RNA
  • Sample Buffer Sds Page
  • Test Kits
  • Vector & Virus
  • Western Blotting Blocking

Recent Posts

  • Serum HER-2 assurance utilizing a centauer HER-2/neu unit (CLIA technique) in metastatic bosom disease
  • Innovative Bioprocess Strategies Combining Physiological Control and Strain Engineering of Pichia pastoris to Improve Recombinant Protein Production
  • fd speedy golgi stain equipment
  • Western Blot Stripping Buffer
  • Protein A, HRP conjugate

Pages

  •  thiol PEG (PEG-SH) linkers Activated PEG Thiol(SH)
  • Advanced Medical Technologies
  • Bill Payment
  • Buster peptide blocker utilization of Background Buster
  • Cell Counting Package deal-8
  • chemical glycerol Triglyceride test definition
  • Contact Us
  • Driving Directions
  • Mycoplasma Detection Kits - Conventional PCR
  • Native DNA preferentially bind DNA presented on PolIV
  • NATtrol Meningitis/Encephalitis (ME) Controls (NATMECBIO)
  • P24 Extended Range Kit ZeptoMetrix HIV Type 1
  • Phone Directory
  • potent necroptosis inhibitor biovision nec 1s
  • PriGrow Media Assortment for mammalian cell custom consists of high-quality
  • Recombinant Antibody Production
  • Registration Information
  • Services Listing
  • Specialty Services
  • SPHERO Ultra Rainbow Fluorescent Particles
  • SPHERO Ultra Rainbow Fluorescent Particles
  • TMB is catalyzed by HRP Enzyme-Linked Immunosorbent Assay
  • total RNA and proteins from exosome samples extracted from biological fluids
  • Viral RNA/DNA titer using qRT-PCR.
  • Volunteer Opportunities

VW Wellness Coach WordPress Theme By VWThemes

Scroll Up